BETHLEHEM, Pa., June 1, 2023 /PRNewswire/ -- Levolta Pharmaceuticals, Inc. has entered into an exclusive licensing and distribution agreement for VOLT01 with Tabuk Pharmaceutical Manufacturing Company of Riyadh, Saudi Arabia, for the commercialization of an investigational osteoarthritis (OA) therapy in the Middle East and Africa (MEA) region, excluding South Africa. VOLT01 is a patented novel combination drug that has shown promise in Phase II and Phase IIb/III clinical trials in treating OA, which has no cure.